The Need of Revisiting to an Outpatient Clinic After the Prescription of Vonoprazan or Esomeprazole
NCT ID: NCT04720781
Last Updated: 2025-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
300 participants
INTERVENTIONAL
2021-01-21
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Open, Randomised, Multi-center Study of on Demand Versus Continuous Esomeprazole Treatment in Patient With GERD
NCT02670642
Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM
NCT06955520
Rate of Complete Symptom Relief, Prevention of Symptom Relapse: Grades A and B Esophagitis of Esomeprazole Therapy
NCT01874535
Indonesian Study of Vonoprazan Vs Esomeprazole in Erosive Esophagitis
NCT06720610
Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis
NCT02388737
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Vonoprazan (20mg/day) or esomeprazole (20mg/day) is prescribed for 4weeks the patients randomly without next appointments.
3. Some patients may visit our outpatient clinic again due to some reasons without any appointments.
4. The number of the patients who revisit our outpatient clinic again is compared with vonoprazan group and esomeprazole.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vonoprazan
Vonoprazan (20mg/day) is prescribed for patients with erosive esophagitis
Vonoprazan
Vonoprazan (20mg/day) is prescribed for 4 weeks.
Esomeprazole
Esomeprazole (20mg/day) is prescribed for patients with erosive esophagitis
Esomeprazole
esomeprazole (20mg/day)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Vonoprazan
Vonoprazan (20mg/day) is prescribed for 4 weeks.
Esomeprazole
esomeprazole (20mg/day)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients have erosive esophagitis diagnosed by esophagogastroduodenoscopy shortly before the prescription
Exclusion Criteria
19 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Showa Inan General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Akira Horiuchi
Chief of Digestive Disease Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Showa Inan General hospital
Komagane, Nagano, Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Revisiting
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.